Sema4 presented research to debunk the belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels.
Read More
The company will offer a 27-gene panel for breast and ovarian cancers, and will also provide NGS-based multi-gene panels for other types of cancer.
Read More
GeneDx now offers its GenomeXpress and GenomeSeqDx whole genome sequencing tests with buccal swabs as an alternative sample collection option for biological parents and other immediate family members.
Read More
Research underscores the positive outcomes of exome sequencing for individuals with ASD, supporting its use to reach a faster diagnosis.
Read More
The transaction, expected for completion later this year, is valued at approximately $1.47 billion.
Read More